Transcode Therapeutics, Inc. reported an acquisition of 100% of ABCJ, LLC on October 8, 2025, issuing 83,285 shares of common stock and up to $95 million in contingent milestones, alongside a private placement of Series B Preferred Stock valued at approximately $25 million.